probenecid has been researched along with Parkinson Disease, Secondary in 10 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three common dosing regimens of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model of Parkinson's disease (PD) were compared in C57BL/6 mice on behavior, striatal and extra-striatal neurotransmission, and brain cytokines, to clarify the differences between regimens on these variables." | 1.35 | Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. ( Luchtman, DW; Shao, D; Song, C, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JG | 1 |
| Huh, E | 1 |
| Ju, IG | 1 |
| Kim, N | 1 |
| Yun, J | 1 |
| Oh, MS | 1 |
| Chen, Y | 2 |
| Zhang, QS | 1 |
| Shao, QH | 2 |
| Wang, S | 2 |
| Yuan, YH | 2 |
| Chen, NH | 2 |
| Wang, HB | 1 |
| Li, FF | 1 |
| Zhang, XL | 1 |
| Al-Jarrah, M | 1 |
| Obaidat, H | 1 |
| Bataineh, Z | 1 |
| Walton, L | 1 |
| Al-Khateeb, A | 1 |
| Luchtman, DW | 1 |
| Shao, D | 1 |
| Song, C | 1 |
| Vanderheyden, JE | 1 |
| Dekoninck, WJ | 1 |
| Lefèvre, A | 1 |
| Mendlewicz, J | 1 |
| Altagracia, M | 1 |
| Rojas, P | 1 |
| Kravzov, J | 1 |
| Rios, C | 1 |
| Miranda, AF | 1 |
| Sutton, MA | 1 |
| Beninger, RJ | 1 |
| Jhamandas, K | 1 |
| Boegman, RJ | 1 |
| Curzon, G | 1 |
| Chase, TN | 1 |
2 reviews available for probenecid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Use of the probenecid test for the diagnosis and treatment of Parkinsonism. Review of the literature and personal experience (author's transl)].
Topics: Aged; Brain; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Middle Aged; Neu | 1980 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
8 other studies available for probenecid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Choline O-Acetyltransferase; Disease Models, | 2018 |
NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Inflammasomes; Male; Mice, I | 2019 |
TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Astrocytes; Corpus Striatum; | 2019 |
Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Male | 2013 |
Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Brain Chemistry; Chromatography, High Pressure Liquid; Cytokines; Inflamm | 2009 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; | 1993 |
Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus.
Topics: Alanine; Animals; Corpus Striatum; Excitatory Amino Acid Antagonists; Hydrolases; Kynurenic Acid; Ky | 1999 |
CSF homovanillic acid: an index of dopaminergic activity.
Topics: Antiparkinson Agents; Brain; Dopamine; Hepatic Encephalopathy; Homovanillic Acid; Humans; Huntington | 1975 |